Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Dec 2024 value amounting to $48.4 million.

  • Mirum Pharmaceuticals' Share-based Compensation rose 52.23% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.6 million, marking a year-over-year increase of 46.17%. This contributed to the annual value of $48.4 million for FY2024, which is 38.32% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Share-based Compensation of $48.4 million as of FY2024, which was up 38.32% from $35.0 million recorded in FY2023.
  • Mirum Pharmaceuticals' 5-year Share-based Compensation high stood at $48.4 million for FY2024, and its period low was $12.6 million during FY2020.
  • Over the past 3 years, Mirum Pharmaceuticals' median Share-based Compensation value was $35.0 million (recorded in 2023), while the average stood at $36.8 million.
  • Data for Mirum Pharmaceuticals' Share-based Compensation shows a peak YoY soared of 106.82% (in 2020) over the last 5 years.
  • Mirum Pharmaceuticals' Share-based Compensation (Yearly) stood at $12.6 million in 2020, then surged by 83.90% to $23.1 million in 2021, then climbed by 16.98% to $27.0 million in 2022, then grew by 29.68% to $35.0 million in 2023, then spiked by 38.32% to $48.4 million in 2024.